Free Trial

aTyr Pharma (LIFE) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
269,400 shs
Average Volume
514,103 shs
Market Capitalization
$131.12 million
P/E Ratio
Dividend Yield
Price Target

aTyr Pharma MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
∞ Upside
$25.50 Price Target
Short Interest
Dividend Strength
News Sentiment
0.00mentions of aTyr Pharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$132,650 Bought Last Quarter
Proj. Earnings Growth
From ($0.89) to ($0.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.71 out of 5 stars

Medical Sector

646th out of 901 stocks

Biological Products, Except Diagnostic Industry

108th out of 152 stocks

LIFE stock logo

About aTyr Pharma Stock (NASDAQ:LIFE)

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

LIFE Stock News Headlines

Collapse of the Petrodollar
The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.
Collapse of the Petrodollar
The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.
Piper Sandler Reaffirms Their Buy Rating on aTyr Pharma (LIFE)
See More Headlines
Receive LIFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Life Sciences Tools & Services
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$1.54 per share


Free Float
Market Cap
$131.12 million

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. Sanjay S. Shukla M.D. (Age 52)
    M.S., President, CEO & Director
    Comp: $768.18k
  • Ms. Jill M. BroadfootMs. Jill M. Broadfoot (Age 62)
    Chief Financial Officer
    Comp: $544.75k
  • Ms. Nancy E. Denyes Krueger (Age 56)
    General Counsel & Corporate Secretary
    Comp: $518.2k
  • Xiang-Lei Yang Ph.D.
  • Ms. Ashlee Dunston
    Director of Investor Relations & Corporate Communications
  • Mr. Peter Villiger
    Vice President of Corporate Development
  • Ms. Danielle Campbell
    VP of Human Resource
  • Dr. Leslie Nangle Ph.D.
    Vice President of Research
  • Dr. Ying J. Buechler Ph.D.
    Executive Director of Biologics Development & Manufacturing
  • Dr. David J. King Ph.D. (Age 65)
    Scientific Consultant
    Comp: $327.31k

LIFE Stock Analysis - Frequently Asked Questions

How were aTyr Pharma's earnings last quarter?

aTyr Pharma, Inc. (NASDAQ:LIFE) posted its earnings results on Thursday, May, 2nd. The biotechnology company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.01. The biotechnology company had revenue of $0.24 million for the quarter, compared to analysts' expectations of $0.11 million.

When did aTyr Pharma's stock split?

aTyr Pharma shares reverse split on the morning of Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 28th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Sanjay Shukla, M.D, M.S's approval rating as aTyr Pharma's CEO?

3 employees have rated aTyr Pharma Chief Executive Officer Sanjay Shukla, M.D, M.S on Sanjay Shukla, M.D, M.S has an approval rating of 100% among the company's employees. This puts Sanjay Shukla, M.D, M.S in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did aTyr Pharma IPO?

aTyr Pharma (LIFE) raised $76 million in an IPO on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

What other stocks do shareholders of aTyr Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Precigen (PGEN) and QUALCOMM (QCOM).

This page (NASDAQ:LIFE) was last updated on 7/24/2024 by Staff

From Our Partners